logo-loader

Summit Therapeutics PLC

Receive alerts
Market:
AIM
Market Cap:
£35.79 m
Price
22.30 GBX
Change
-3.04%
52 weeks high
34.67
52 weeks low
9.50

In brief

Summit Therapeutics is a leader in antibiotic innovation. Summit’s new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. The company is currently developing new mechanism antibiotics for infections caused by C. difficile, N. Gonorrhoeae and ESKAPE pathogens and is using its proprietary Discuva Platform to expand its pipeline.

Deep dive We explore the investor case for growth companies

Snapshot

Summit Therapeutics' potential breakthrough targets C.difficile